Development of Pathology-activated Drugs for Treatment of Neuropathic Pain — Andrew Abell (UNIVERSITY OF TX MD ANDERSON CAN CTR)
Current therapeutics for neuropathic pain are poorly efficacious. One likely reason is that current therapies target only a single biochemical mechanism or pathway while chronic pain is a multi-mechan
| Project title | Development of Pathology-activated Drugs for Treatment of Neuropathic Pain |
|---|---|
| Project number | 1UG3NS127251-01A1 |
| PI name | Andrew Abell |
| Institution | UNIVERSITY OF TX MD ANDERSON CAN CTR |
| Funding mechanism | UG3 |
| Agency | NINDS |
| Award amount | $2.41M |
| Fiscal year | 2022 |
| Project start | 2022-09-20T00:00:00 |
| Project end | 2024-08-31T00:00:00 |
| Abstract | Current therapeutics for neuropathic pain are poorly efficacious. One likely reason is that current therapies target only a single biochemical mechanism or pathway while chronic pain is a multi-mechan |
| Key terms | <Adverse Experience><Adverse effects><Adverse event><Analgesic Agents><Analgesic Drugs><Analgesic Pr |
$799/mo
Try GrantRadar →